Trial reportApplied immunohistochemistry & molecular morphology : AIMM2012
Laminin 332 expression in breast carcinoma.
Trial report in Applied immunohistochemistry & molecular morphology : AIMM, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Immunohistochemical Expression of Laminin 332 in Triple-Negative Breast Carcinoma: A Cross-Sectional Study.Cureus · 2025Article
- Review
- Exploring the interaction between extracellular matrix components in a 3D organoid disease model to replicate the pathophysiology of breast cancer.Journal of experimental & clinical cancer research : CR · 2023Review
- Migration speed of captured breast cancer subpopulations correlates with metastatic fitness.Journal of cell science · 2023Article
- HPV-Associated Breast Cancer: Myth or Fact?Pathogens (Basel, Switzerland) · 2022Review
- Breast cancer models: Engineering the tumor microenvironment.Acta biomaterialia · 2020Review
- Article
- Tissue engineering and regenerative medicine strategies for the female breast.Journal of tissue engineering and regenerative medicine · 2020Review
- Laminin 332 expression and prognosis in breast cancer.Human pathology · 2018Article
- Nanoscale Topography and Poroelastic Properties of Model Tissue Breast Gland Basement Membranes.Biophysical journal · 2018Article
- Engineering Breast Cancer Microenvironments and 3D Bioprinting.Frontiers in bioengineering and biotechnology · 2018Review
- Migration of breast cancer cell lines in response to pulmonary laminin 332.Cancer medicine · 2017Article
- SPR imaging biosensor for determination of laminin-5 as a potential cancer marker in biological material.Analytical and bioanalytical chemistry · 2016Article
- Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer.BMC cancer · 2014Article
- Integrin α3β1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.Molecular cancer research : MCR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Laminin 332 (LN332) is a basally expressed extracellular matrix protein that enhances the migration and invasion of breast carcinoma cells. The goal of this study was to examine LN332 expression breast carcinoma. Triple negative breast carcinomas lack estrogen receptor (ER), progesterone receptor (PR) expression and HER2 positivity. Immunohistochemistry for ER, PR, HER2, and dual silver in situ hybridization for the HER2 gene were used to define the phenotype of 243 breast cancers in biopsies or arrays. Immunohistochemistry for LN332 revealed that 70% of triple negative carcinomas stained for LN332. Cytokeratins 5/6 (CK5/6), epidermal growth factor receptor and p63 alone stained fewer triple negative breast carcinomas each, but the combination of LN332 and CK5/6 or epidermal growth factor receptor identified 92% of triple negative breast carcinoma. Of the 163 non-triple negative cases, LN332 was expressed in only 15%. The identification of LN332 in triple negative breast carcinomas is consistent with gene profiling studies showing its expression among breast carcinomas with a basal phenotype. The observation that a proinvasive protein such as LN332 is expressed in breast cancer suggests another mechanism by which the triple negative phenotype could be aggressive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.